Thieler Law Corp, member of the Investor Attorney Network, is investigating whether certain officers and directors of Myriad Genetics Inc (NASDAQ: MYGN) violated securities laws in connection with certain financial statements.

The investigation seeks to discover if possible claims on behalf of purchasers of the securities of Myriad Genetics Inc (NASDAQ: MYGN) concerning whether a series of statements by Myriad Genetics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

On March 12, 2018, the Company revealed that it received a subpoena from the Department of Health and Human Services in connection with an investigation into possible false Medicare and Medicaid payment claims. The subpoena purportedly requested documents “relating primarily to the Company’s billing to government-funded healthcare programs for the Company’s hereditary cancer testing.”

Following this news, NASDAQ: MYGN fell $4.01 per share, or 12.1%, to close at $29.01 per share on March 13, 2018, thereby injuring investors.

Based in Salt Lake City, Utah, and founded in 1991 Myriad Genetics Inc a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide.

If you purchased shares of Myriad Genetics Inc (NASDAQ: MYGN) on or before March 12, 2018, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185